Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Mauriac L, Keshaviah A, Debled M, Mouridsen H, Forbes JF, Thürlimann B, Paridaens R, Monnier A, Láng I, Wardley A, Nogaret JM, Gelber RD, Castiglione-Gertsch M, Price KN, Coates AS, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A; BIG 1-98 Collaborative Group; International Breast Cancer Study Group. Mauriac L, et al. Among authors: thurlimann b. Ann Oncol. 2007 May;18(5):859-67. doi: 10.1093/annonc/mdm001. Epub 2007 Feb 14. Ann Oncol. 2007. PMID: 17301074 Free article. Clinical Trial.
First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research.
Borner M, Bacchi M, Goldhirsch A, Greiner R, Harder F, Castiglione M, Jungi WF, Thürlimann B, Cavalli F, Obrecht JP, et al. Borner M, et al. Among authors: thurlimann b. J Clin Oncol. 1994 Oct;12(10):2071-7. doi: 10.1200/JCO.1994.12.10.2071. J Clin Oncol. 1994. PMID: 7931476 Clinical Trial.
First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88.
Thürlimann B, Beretta K, Bacchi M, Castiglione-Gertsch M, Goldhirsch A, Jungi WF, Cavalli F, Senn HJ, Fey M, Löhnert T. Thürlimann B, et al. Ann Oncol. 1996 Jul;7(5):471-9. doi: 10.1093/oxfordjournals.annonc.a010635. Ann Oncol. 1996. PMID: 8839901 Free article. Clinical Trial.
Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI.
Goldhirsch A, Gelber RD, Castiglione M, O'Neill A, Thürlimann B, Rudenstam CM, Lindtner J, Collins J, Forbes J, Crivellari D, Coates A, Cavalli F, Simoncini E, Fey MF, Pagani O, Price K, Senn HJ. Goldhirsch A, et al. Among authors: thurlimann b. Ann Oncol. 1997 Aug;8(8):751-6. doi: 10.1023/a:1008220301866. Ann Oncol. 1997. PMID: 9332682 Free article. Clinical Trial.
Exemestane experience in breast cancer treatment.
Lønning PE, Paridaens R, Thürlimann B, Piscitelli G, di Salle E. Lønning PE, et al. Among authors: thurlimann b. J Steroid Biochem Mol Biol. 1997 Apr;61(3-6):151-5. J Steroid Biochem Mol Biol. 1997. PMID: 9365185 Review.
Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK).
Thürlimann B, Castiglione M, Hsu-Schmitz SF, Cavalli F, Bonnefoi H, Fey MF, Morant R, Löhnert T, Goldhirsch A. Thürlimann B, et al. Eur J Cancer. 1997 Jun;33(7):1017-24. doi: 10.1016/s0959-8049(97)00105-6. Eur J Cancer. 1997. PMID: 9376181 Clinical Trial.
Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group.
Thürlimann B, Paridaens R, Serin D, Bonneterre J, Roché H, Murray R, di Salle E, Lanzalone S, Zurlo MG, Piscitelli G. Thürlimann B, et al. Eur J Cancer. 1997 Oct;33(11):1767-73. doi: 10.1016/s0959-8049(97)00283-9. Eur J Cancer. 1997. PMID: 9470830 Clinical Trial.
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI.
Pagani O, O'Neill A, Castiglione M, Gelber RD, Goldhirsch A, Rudenstam CM, Lindtner J, Collins J, Crivellari D, Coates A, Cavalli F, Thürlimann B, Simoncini E, Fey M, Price K, Senn HJ. Pagani O, et al. Among authors: thurlimann b. Eur J Cancer. 1998 Apr;34(5):632-40. doi: 10.1016/s0959-8049(97)10036-3. Eur J Cancer. 1998. PMID: 9713266 Clinical Trial.
Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG).
Bernhard J, Hürny C, Coates AS, Peterson HF, Castiglione-Gertsch M, Gelber RD, Galligioni E, Marini G, Thürlimann B, Forbes JF, Goldhirsch A, Senn HJ, Rudenstam CM. Bernhard J, et al. Among authors: thurlimann b. Br J Cancer. 1998 Sep;78(5):686-93. doi: 10.1038/bjc.1998.561. Br J Cancer. 1998. PMID: 9744512 Free PMC article.
232 results